4M Healthcare, LLC

4M Healthcare, LLC was paid $1.73M by Medicaid between Jan 2018 and Nov 2024, across 69 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 35% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kansas

Rank by total paid#7 of 47

Median peer was paid$64K

This provider vs. median27×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	9,521	$86K
2019	32,871	$322K
2020	38,994	$607K
2021	12,919	$386K
2022	6,914	$199K
2023	1,449	$64K
2024incomplete	999	$66K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	35%	15,342	6,594	$599K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	19%	4,589	4,078	$323K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	11%	1,424	1,238	$198K
87505		2.6%	737	634	$46K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.5%	1,220	1,130	$43K
80355		1.4%	2,450	2,219	$24K
80366		1.3%	2,298	2,083	$23K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.3%	936	857	$22K
87653		1.1%	1,034	876	$19K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.0%	994	854	$18K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.0%	995	854	$18K
80346		<1%	2,850	2,572	$17K

57 more codes

80336		<1%	1,039	$16K
87640		<1%	1,009	$16K
80348		<1%	2,929	$14K
80321		<1%	1,487	$14K
80358		<1%	2,934	$14K
80359		<1%	2,943	$14K
80360		<1%	2,440	$13K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	207	$13K
80368		<1%	2,039	$13K
80343		<1%	1,245	$13K
80323		<1%	1,820	$12K
80349		<1%	2,586	$12K
80345		<1%	2,847	$12K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	695	$11K
87500		<1%	1,205	$11K
80373		<1%	2,522	$9K
80371		<1%	1,877	$9K
87563		<1%	566	$8K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	437	$8K
80372		<1%	2,254	$8K
80369		<1%	1,850	$8K
80356		<1%	2,779	$8K
80365		<1%	2,960	$8K
87529		<1%	988	$8K
80354		<1%	2,957	$7K
80353		<1%	2,819	$7K
80350		<1%	1,147	$7K
87481		<1%	911	$7K
87632		<1%	66	$7K
80320		<1%	579	$7K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	2,647	$6K
80375		<1%	704	$5K
80364		<1%	1,206	$5K
80335		<1%	440	$4K
80338		<1%	650	$4K
80325		<1%	1,045	$4K
87556		<1%	668	$4K
80324		<1%	1,893	$4K
80342		<1%	440	$3K
80337		<1%	236	$3K
83992		<1%	474	$3K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	31	$3K
80361		<1%	1,610	$3K
87631		<1%	569	$3K
80357		<1%	514	$2K
87109		<1%	387	$2K
80362		<1%	1,164	$1K
87486		<1%	341	$1K
87581		<1%	338	$1K
87541		<1%	287	$842.14
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	68	$835.84
80334		<1%	32	$661.20
87532		<1%	237	$587.74
87496		<1%	27	$151.60
87641		<1%	27	$140.29
80332		<1%	427	$136.80
80363		<1%	199	$55.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMANN, JERRED (CEO)